Compare EARN & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | CVRX |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 200.3M | 201.0M |
| IPO Year | 2013 | 2021 |
| Metric | EARN | CVRX |
|---|---|---|
| Price | $5.62 | $5.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.88 | ★ $13.17 |
| AVG Volume (30 Days) | ★ 338.6K | 257.5K |
| Earning Date | 02-20-2026 | 02-03-2026 |
| Dividend Yield | ★ 17.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $35,893,000.00 | ★ $55,969,000.00 |
| Revenue This Year | $8.43 | $11.91 |
| Revenue Next Year | $17.28 | $15.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 43.30 | 18.44 |
| 52 Week Low | $4.33 | $4.30 |
| 52 Week High | $6.82 | $18.55 |
| Indicator | EARN | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 23.14 |
| Support Level | $5.23 | $5.34 |
| Resistance Level | $5.57 | $6.09 |
| Average True Range (ATR) | 0.10 | 0.65 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 100.00 | 1.43 |
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times. The company primary investment objectives are to generate attractive current yields and risk-adjusted total returns for shareholders. It invest in multiple parts of the CLO capital structure, principally mezzanine debt and equity tranches. Rather than focusing only on short-term current yield, it select investments that it believe will provide a strong total return to drive a sustainable earnings stream over a long-term horizon.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.